Erwin P Bottinger, MD
- PROFESSOR | Medicine, Nephrology
- PROFESSOR | Pharmacological Sciences
Research Topics:
Apoptosis/Cell Death, Bioinformatics, Cell Biology, Diabetes, Fibrosis, Genomics, Growth Factors and Receptors, Kidney, Knockout Mice, Signal TransductionEducation
Nuremberg General Hospital, University of ErIangen-Nuremberg
Cabrini Medical Center
Massachusetts General Hospital and Harvard Medical School
National Cancer Institute, National Institutes of Health
MD, Friedrich-Alexander Universitat School of Medicine, Erlangen-Nurember
Early pathomechanisms in diabetic nephropathy and non-diabetic kidney diseases
Millions of Americans are affected with chronic diabetic and non-diabetic kidney diseases that cause kidney failure (end stage renal disease). When kidneys fail, the average life expectancy is just over two years and survival depends on costly and disabling dialysis or transplantation treatments.
State-of-the-art genomics and bioinformatics approaches are used to discover and characterize new molecular targets and pathways associated with apoptosis, transdifferentiation, and fibrogenesis in specialized renal cells exposed to diabetic and other stresses. TGF-beta signaling pathways and targets are a major theme because TGF-beta is a key mediator of these processes.
Model systems used include renal cell culture and mouse models of diabetic and non-diabetic progressive renal disease. A new genomic medicine program aims at identification and validation of molecular biomarkers that predict progressive kidney disease in humans.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Bottinger during 2018 and/or 2019. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Ontomics, Inc.
Service on Board of Directors: Service in a fiduciary capacity, such as an officer or director, for the following companies:
- Ontomics, Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.